Needham Initiates Coverage On Definitive Healthcare with Buy Rating, Announces Price Target of $30
Needham analyst Ryan MacDonald initiates coverage on Definitive Healthcare (NASDAQ:DH) with a Buy rating and announces Price Target of $30.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
4 Analysts Have This to Say About Definitive Healthcare
Analysts have provided the following ratings for Definitive Healthcare (NASDAQ:DH) within the last quarter:
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Deutsche Bank Maintains Hold on Definitive Healthcare, Raises Price Target to $26
Deutsche Bank analyst George Hill maintains Definitive Healthcare (NASDAQ:DH) with a Hold and raises the price target from $21 to $26.
Credit Suisse Maintains Neutral on Definitive Healthcare, Lowers Price Target to $24
Credit Suisse analyst Jailendra Singh maintains Definitive Healthcare (NASDAQ:DH) with a Neutral and lowers the price target from $30 to $24.
UPDATE: Definitive Healthcare Q4 Adj. EPS $0.04, Inline, Sales $46.31M Beat $44.62M Estimate
Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. The company reported quarterly sales of $46.31 million which beat the analyst consensus estimate
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
Deutsche Bank Maintains Hold on Definitive Healthcare, Lowers Price Target to $21
Deutsche Bank analyst George Hill maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $45 to $21.
Expert Ratings For Definitive Healthcare
Over the past 3 months, 5 analysts have published their opinion on Definitive Healthcare (NASDAQ:DH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.